The pharmaceutical composition is a combination of hydrolytic
lignin with
moisture of 55% to 65% consisting of the particles measuring 0.15 mm to 0.55 mm, a 45% to 55% aqueous
lactulose solution, and a 50% to 55% aqueous
oligosaccharide solution at the following ingredient ratio (weight percent): 10-60 of an aqueous
lactulose solution; 10-60 of oligosaccharides; sufficient quantity of hydrolytic
lignin. Hydrolytic
lignin,
lactulose and
fructose oligosaccharides are sequentially added and mixed using a rotor blender. The composition is administered orally for no less than 14 days and no more than 30 days, two to four times a day, depending on the patient's weight and age. The composition is used as a
medicine for treatment of the gastrointestinal disorders, including bacterial, viral, protozoal enteric infections,
food poisoning, acute and
chronic hepatitis and
cirrhosis,
diarrhea,
peptic ulcer, Crohn's
disease,
ulcerative colitis,
irritable bowel syndrome, mineral disorders with Ca / Mg deficiency, including
osteoporosis and other alterations of the
bone formation, as an immunomodulator in
atopic dermatitis and
immunodeficiency conditions, for protection and
recovery of intestinal
flora after
antibiotic therapy,
chemotherapy, and radiotherapy. The result is accelerated achievement of the effect and the enhanced action on the state of intestinal microbiocenosis as well as increased effectiveness of treatment of
hepatitis and liver
cirrhosis,
elimination of undesired adverse effects in clinical usage, and extension of indications, i.e. the extended spectrum of usage in prevention and treatment.